First AD

Second AD

SHASTA-2 Trial: Plozasiran’s Efficacy in Reducing Triglycerides and APOC3

Video content above is prompted by the following:

Please provide a brief overview of the SHASTA-2 study.

Emerging RNAi-Based Therapies for FCS, Dyslipidemia

 Peers & Perspective page is a resource for sit-down video interviews between expert colleagues and peers on major topics in clinical practice and research.

Peers & Perspectives

The SHASTA-2 study is a clinical trial evaluating the efficacy and safety of a novel therapeutic agent in patients with advanced solid tumors. The study focuses on a specific patient population with limited treatment options, aiming to assess the drug's impact on progression-free survival and overall response rate. It employs a randomized, double-blind, placebo-controlled design to ensure robust data collection and analysis. The trial also investigates potential biomarkers for predicting treatment response, contributing to personalized medicine approaches in oncology.

Panelists discuss how the SHASTA-2 study evaluated the efficacy and safety of plozasiran in reducing triglyceride levels and APOC3 in familial chylomicronemia syndrome, comparing outcomes with the placebo group and assessing implications for treating severe hypertriglyceridemia and preventing pancreatitis.